secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELI LILLY & Co (LLY)
CIK:        0000059478
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0000059478-22-000194
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lilly Q2 EPS $1.05 ($1.25 non-GAAP); revenue down 4% to $6.49B; key growth products up 20%
--------------------------------------------------------------------------------

- Revenue $6,488M (-4% YoY; -1% constant currency); core revenue up 6% excluding Alimta, Cialis rights sale, COVID antibodies.
- Reported EPS $1.05 (-31%); non-GAAP EPS $1.25 (-32%); both include $0.46 acquired IPR&D charges.
- Key growth products (Trulicity, Verzenio, Jardiance etc.) grew 20% to 67% of revenue (ex COVID antibodies).
- 2022 guidance: reported EPS $6.96-$7.11, non-GAAP $7.90-$8.05; revenue guidance unchanged.
- FDA accepted donanemab (Alzheimer's) and pirtobrutinib (MCL) with Priority Review; Mounjaro approved for T2D; Olumiant for alopecia areata.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/59478/000005947822000194/0000059478-22-000194-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/59478/000005947822000194/lly-20220804.htm
  HTML page:      https://secwatch.observer/filing/0000059478-22-000194

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer